Download full-text


Available from: Gary Siuzdak, Jan 16, 2014
1 Follower
53 Reads
  • Source
    • "This has prompted research into suitable alternatives to viral and plasmid reprogramming (Okita et al., 2008; Woltjen et al., 2009; Yu et al., 2009; Zhou et al., 2009; Li et al., 2011; Worsdorfer et al., 2013; Talluri et al., 2014). The SB and PB transposon systems share many advantages for mediating epigenetic reprogramming, and possess a high cargo capacity of >100 kb (Rostovskaya et al., 2012). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Induced pluripotent stem cells (iPSCs) are a seminal breakthrough in stem cell research and are promising tools for advanced regenerative therapies in humans and reproductive biotechnology in farm animals. iPSCs are particularly valuable in species in which authentic embryonic stem cell (ESC) lines are yet not available. Here, we describe a nonviral method for the derivation of bovine iPSCs employing Sleeping Beauty (SB) and piggyBac (PB) transposon systems encoding different combinations of reprogramming factors, each separated by self-cleaving peptide sequences and driven by the chimeric CAGGS promoter. One bovine iPSC line (biPS-1) generated by a PB vector containing six reprogramming genes was analyzed in detail, including morphology, alkaline phosphatase expression, and typical hallmarks of pluripotency, such as expression of pluripotency markers and formation of mature teratomas in immunodeficient mice. Moreover, the biPS-1 line allowed a second round of SB transposon-mediated gene transfer. These results are promising for derivation of germ line-competent bovine iPSCs and will facilitate genetic modification of the bovine genome.
    Cellular Reprogramming 04/2015; DOI:10.1089/cell.2014.0080. · 1.79 Impact Factor
  • Source
    • "Even the seemingly straightforward DNA-free non-integrating methods [e.g. small molecule cocktails (Hou et al, 2013) or proteins (Zhou et al, 2009)] remain highly inefficient, requiring intricate protocols with multiple rounds of treatment, large doses, and uncontrolled presence/kinetics of reprogramming factors. Thus, new strategies are required to overcome the limitations associated with these traditional reprogramming methods. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Derived from any somatic cell type and possessing unlimited self-renewal and differentiation potential, induced pluripotent stem cells (iPSCs) are poised to revolutionize stem cell biology and regenerative medicine research, bringing unprecedented opportunities for treating debilitating human diseases. To overcome the limitations associated with safety, efficiency, and scalability of traditional iPSC derivation, expansion, and differentiation protocols, biomaterials have recently been considered. Beyond addressing these limitations, the integration of biomaterials with existing iPSC culture platforms could offer additional opportunities to better probe the biology and control the behavior of iPSCs or their progeny in vitro and in vivo. Herein, we discuss the impact of biomaterials on the iPSC field, from derivation to tissue regeneration and modeling. Although still exploratory, we envision the emerging combination of biomaterials and iPSCs will be critical in the successful application of iPSCs and their progeny for research and clinical translation. © 2015 The Authors.
    The EMBO Journal 03/2015; 34(8). DOI:10.15252/embj.201490756 · 10.43 Impact Factor
  • Source
    • "Some of these techniques are grounded on the almost complete removal of the integrated viral DNA or alternatively, on the use of nonintegrating viruses [17,18]. Furthermore, the launch of virus-independent reprogramming methods based on DNA, protein, or mRNA expression is expected to further improve iPSC quality [19,20,21]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Induced pluripotent stem cells (iPSCs) were first described in 2006 and have since emerged as a promising cell source for clinical applications. The rapid progression in iPSC technology is still ongoing and directed toward increasing the efficacy of iPSC production and reducing the immunogenic and tumorigenic potential of these cells. Enormous efforts have been made to apply iPSC-based technology in the clinic, for drug screening approaches and cell replacement therapy. Moreover, disease modeling using patient-specific iPSCs continues to expand our knowledge regarding the pathophysiology and prospective treatment of rare disorders. Furthermore, autologous stem cell therapy with patient-specific iPSCs shows great propensity for the minimization of immune reactions and the provision of a limitless supply of cells for transplantation. In this review, we discuss the recent updates in iPSC technology and the use of iPSCs in disease modeling and regenerative medicine.
    The Korean Journal of Internal Medicine 09/2014; 29(5):547-557. DOI:10.3904/kjim.2014.29.5.547 · 1.43 Impact Factor
Show more